Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Treatment of Opioid Use Disorder: Waiver Qualifying - University Center, MI - Friday, November 13, 2020

    Product not yet rated Contains 3 Component(s), Includes Credits Includes a Live In-Person Event on 11/13/2020 at 8:00 AM (EST)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: Michigan Opioid Collaborative

    Friday, November 13, 2020 | 8:00 am - 5:00 pm

    Saginaw Valley State University
    GS202
    7400 Bay Road
    University Center, MI 48710

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please log in to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: July 2023

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Troy, MI - Friday, October 9, 2020

    Product not yet rated Contains 4 Component(s), Includes Credits Includes a Live In-Person Event on 10/09/2020 at 8:00 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: Michigan Opioid Collaborative

    Friday, October 9, 2020 | 8:00 am - 5:00 pm

    Michigan State University (MSU) Management Education Center (MEC)
    (Amphitheatre 101)
    811 W Square Lake Rd.
    Troy, MI 48098 

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please log in to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: July 2023

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Marquette, MI - Friday, September 25, 2020

    Product not yet rated Contains 4 Component(s), Includes Credits Includes a Live In-Person Event on 09/25/2020 at 8:00 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: Michigan Opioid Collaborative

    Friday, September 25, 2020 |8:00 am - 5:00 pm

    Upper Peninsula Health Plan
    853 West Washington Street
    Marquette, Michigan 49855

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please LOG IN to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Please park in the UPHP parking lot (off of main entrance). Additional parking along the front of Staybridge Suites (avoid parking at mBank). Upon arrival, please register at reception and a UPHG representative will meet you and take you to the conference room located on the second floor.

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: July 2023

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Grand Rapids, MI - Monday, September 21, 2020

    Product not yet rated Contains 4 Component(s), Includes Credits Includes a Live In-Person Event on 09/21/2020 at 8:00 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: Michigan Center for Clinical Systems Improvement

    Monday, September 21, 2020 | 8:00 am - 5:00 pm

    Kent County Health Department
    700 Fuller Ave NE
    Grand Rapids, MI 49503

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please log in to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: July 2023

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Traverse City, MI - Monday, August 31, 2020

    Product not yet rated Contains 4 Component(s), Includes Credits Includes a Live In-Person Event on 08/31/2020 at 8:00 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: Michigan Opioid Collaborative

    Monday, August 31, 2020 | 8:00 am - 5:00 pm

    The Hagerty Center
    Rm A+B
    715 E. Front St.
    Traverse City, MI 49686

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please log in to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: December 2019

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AAPA Credit Designation Statement

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee


    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAMNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received? Stock 
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVS None
    Tricia E. Wright, MD, MS, FACOG, DFASAM None


    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD (Chair)None
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRONone
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Sandy MetcalfeNone


    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartNone

    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Virginia Department of Health - Wednesday, August 26, 2020

    Product not yet rated Contains 6 Component(s), Includes Credits Includes a Live Web Event on 08/26/2020 at 9:00 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image
    image

    image

    Host: Virginia Department of Health

    Date: Wednesday, August 26, 2020 | 9:00 am - 1:00 pm ET

    REAL TIME VIRTUAL LEARNING IN ZOOM

    Online Portion Due: Tuesday, August 25, 2020

    Overview 

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
    This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course. 

    Getting Started 

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions.If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: July 2023

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to csatbupinfo@dsgonline.com. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Nashville, TN - Friday, July 31, 2020

    Product not yet rated Contains 7 Component(s), Includes Credits Includes a Live Web Event on 07/31/2020 at 9:30 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

    Host: Tennessee Initiative for Perinatal Quality Care

    Friday, July 31, 2020 | 8:30 am CT - 1:00 pm CT

    Via Live Webinar 

    Online Portion Due: Thursday, July 30, 2020

    This course is offered in partnership with the American College of Obstetricians and Gynecologists (ACOG). The curriculum for this course has been specifically designed for women's health providers.

    Overview

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live webinar learning. The live webinar portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live webinar portion. You must complete both portions to receive credit for the course. 

    Register in advance for this webinar here: https://us02web.zoom.us/webina...

    After registering, you will receive a confirmation email containing information about joining the webinar.

    Getting Started

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    1. Identify the importance of screening for substance use disorders
    2. Describe the mechanism of opioid withdrawal
    3. Discuss options to treat opioid withdrawal
    4. Explain the safety and efficacy of buprenorphine to treat opioid use disorder
    5. Explain the safety of medications in antepartum, postpartum, and breastfeeding period
    6. Describe how to start a patient (induction) on buprenorphine in an office-based setting
    7. Discuss successful non-pharmacological ways to treat Neonatal Abstinence Syndrome

    Overall Objective

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder.

    Target Audience

    1. Physicians, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and Clinical Nurse Specialists who wish to obtain a waiver to prescribe buprenorphine in an office-based setting for opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.
    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to csatbupinfo@dsgonline.com. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Madison, WI - Thursday, July 30, 2020

    Product not yet rated Contains 6 Component(s), Includes Credits Includes a Live Web Event on 07/30/2020 at 1:00 PM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

    Host: University of Wisconsin Family Medicine Residency

    Thursday, July 30, 2020 | 12:00 pm - 5:00 pm

    Remote Live Webinar

    Online Portion Due: Wednesday, July 29, 2020

    Overview 

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
    This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course. 

    Getting Started 

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions.If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    Module 1  (Online)

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2 (Online)

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3 (Live)

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Module 4 (Live)

    Case Studies

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: July 2023

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Virginia Department of Health - Wednesday, July 29, 2020

    Product not yet rated Contains 6 Component(s), Includes Credits Includes a Live Web Event on 07/29/2020 at 9:00 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image
    image

    image

    Host: Virginia Department of Health

    Date: Wednesday, July 29, 2020 | 9:00 am - 1:00 pm ET

    REAL TIME VIRTUAL LEARNING IN ZOOM

    Online Portion Due: Tuesday, July 28, 2020

    Overview 

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
    This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course. 

    Getting Started 

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions.If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: July 2023

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to csatbupinfo@dsgonline.com. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - NVPCA - Monday, July 20, 2020

    Product not yet rated Contains 3 Component(s), Includes Credits Includes a Live Web Event on 07/27/2020 at 11:00 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

    Host: Nevada Primary Care Association

    Monday, July 20, 2020 | 8:00 am - 5:00 pm PT

    Live Webinar

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please log in to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Target Audience

    1. Physicians, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and Clinical Nurse Specialists who wish to obtain a waiver to prescribe buprenorphine in an office-based setting for opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    Daniel A. Nauts, MD, FASAM

    Dr. Nauts, MD, FASAM completed his undergraduate and medical education at the University of Michigan and joined an internal medicine group practice in Bellingham, Washington.  He left general internal medicine to develop his Addiction Medicine practice; since that time, he has been instrumental in the creation of 3 inpatient programs for those suffering with substance use and co-occurring disorders, outpatient SUD programs, and medication assisted treatment services. 

    Dr. Nauts is an independent contractor for the Montana Primary Care Association providing MAT waiver trainings and technical assistance, community forums on opioid use disorders, academic detailing activities for MAT providers, and helping in strategies to taper patients off high dose morphine equivalents.  Not only is he committed to integrating addiction medicine into primary care but also in promoting the development of more addiction medicine specialists in Montana.

    He is active in the American Society of Addiction Medicine (ASAM), delivers a myriad of presentations for any professional or public audience, has participated in addressing physician and nurse health issues through Professional Assistance Programs, and has provided Addiction Medicine experiences for residents of the Western Montana Family Practice Program and PA students from the University of Washington Medex Program.

    He is a member of the Drug Utilization Board of Mountain Pacific Quality Health providing oversight to the Medicaid formulary, is recognized as a Fellow of the American Society of Addiction Medicine (FASAM), and is certified in the subspecialty of Addiction Medicine by the American Board of Preventive Medicine.  He is the treasurer for the Northwest Society of Addiction Medicine, a Chapter of American Society of Addiction Medicine (ASAM) representing Montana, North Dakota, and Wyoming and is a faculty member of ASAM to provide Data 2000 MAT waiver trainings and The Fundamentals of Addiction Medicine.

    Dr. Nauts is the 2019 recipient of the Award of Merit presented by the Montana Medical Association honoring the work he has done to improve healthcare in Montana. 

    Frank Del Real, MD, FASAM

    Dr. Frank Del Real is the Medical Director at Central Wyoming Counseling Center and Clinical Adjunct Professor and Visiting Attending at the University of Wyoming Family Practice Program. Previously, he was the Medical Director at Wyoming Recovery. Dr. Del Real attended medical school at the University of California, San Diego where he received his M.D. degree. He then completed his residency in Psychiatry at Harbor, UCLA Medical Center. He has practiced as a psychiatrist for 31 years. In addition to his extensive experience in psychiatry he is also Board Certified in addiction medicine. He is one of a few physicians in Wyoming that provides out-patient based opioid treatment for those suffering from opioid use disorders. He is an active member of the American Society of Addiction Medicine (ASAM) where he serves as chairman of the membership committee of the Northwest chapter. He is the immediate past-president of the Northwest Chapter. He was also a member of the ASAM Marijuana Task Force that contributed to the development of the Marijuana Position Paper for ASAM.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 8 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to csatbupinfo@dsgonline.com. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.